8 new oncology trials approved in Europe
 |
Oncology Hero |
8 new oncology trials approved in Europe
Good morning, here is a concise selection of oncology and haematology trials recently authorised in Europe.
RINGQUEST: Exploring Understudied Genitourinary Tumors with Sacituzumab Tirumotecan; a Single-arm, Basket, Phase II Study.
| Sponsor: Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator Interest[18F] MC225 PET analysis of Blood-Brain Barrier Function in Glioblastomas
| Sponsor: Universitair Medisch Centrum Groningen | Phase: |
Interested in offering this trial to suitable patients?
Register Investigator InterestPHOENIX-ECP: A Phase 2, Randomized, Controlled, Open-label, Multicenter Study to Evaluate the Efficacy and Safety/Tolerability of Extracorporeal Photopheresis (ECP) Versus Best Available Therapy (BAT) for the Treatment of Immune-related Colitis and/or Hepatitis with Inadequate Response to Corticosteroids in Participants with Unresectable or Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
| Sponsor: Therakos Europe Limited | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA phase 2, open-label, Multicenter, Randomized study of Trastuzumab Deruxtecan versus investigator’s choice chemotherapy in recurrent ovarian cancer that progressed on prior PARP inhibitor therapy: TROY (APGOT-OV14)
| Sponsor: Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA Phase 1/2, Multicenter, First-in-Human, Dose Escalation and Expansion Study Evaluating CHM-029, as Monotherapy and in Combination with Standard Therapies in Participants with Relapsed or Refractory, or Newly Diagnosed Acute Myeloid Leukemia (AML) with NPM1 Mutations, KMT2A or NUP98 Rearrangements
| Sponsor: Charm Therapeutics Limited | Phase: 1, 2 |
Not accepting new sites
Pharmacokinetic study of pembrolizumab and its impact on immunity and the tumor microenvironment, which may explain the efficacy of post-immunotherapy chemotherapy
| Sponsor: Centre Antoine Lacassagne | Phase: 4 |
Not accepting new sites
PROOF OF CONCEPT: FEASIBILITY OF PHOTODYNAMIC DIAGNOSIS IN BLADDER CANCER PATIENTS WITH SUB-ONE-HOUR INSTILLATION TIME OF HEXAMINOLEVULINATE (HEXVIX®)
| Sponsor: Institut Paoli Calmettes | Phase: 2 |
Not accepting new sites
ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination with Ipilimumab or Cabozantinib in Participants with Advanced Renal Cell Carcinoma (RCC)
| Sponsor: Bristol-Myers Squibb Services Unlimited Company | Phase: 1, 2 |
Not accepting new sites
Oncology Hero Trial Feed connects oncology professionals with relevant clinical trials.
For qualified healthcare and research professionals. Registration expresses investigator interest; it is not patient enrollment.
Oncology Hero
Sharing the latest updates in oncology
Oncology Hero 15 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials first authorised in Europe in the last week. Use of the Checkpoint inhibitor DOstarlimab in the endOmetrial cancer fertility-Sparing trEatment: CHOOSE study Sponsor: UZ Leuven Phase: 2 Interested in offering this trial to suitable patients? Register Investigator Interest Antibody-based PET imaging and treatment response in breast cancer treated with an...
Oncology Hero 6 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials first authorised in Europe in the last week. A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL) Sponsor: Oslo Universitetssykehus HF Phase: Not specified Interested in offering this trial to suitable patients? Register Investigator Interest A Phase 3 Randomized Study...
Oncology Hero 6 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials first authorised in Europe in the last week. Pilot study with Low-dose nivolumab in Advanced Neoplasms that are TMB-high Sponsor: UZ Brussel Phase: 2 Interested in offering this trial to suitable patients? Register Investigator Interest Randomized study evaluating the impact of an innovative and cooperative pathway integrating OncoGeriatric, pharmaceutical and...